Edition:
United States

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

259.20DKK
10:59am EDT
Change (% chg)

kr.-2.60 (-0.99%)
Prev Close
kr.261.80
Open
kr.261.80
Day's High
kr.265.50
Day's Low
kr.259.20
Volume
340,279
Avg. Vol
321,082
52-wk High
kr.476.40
52-wk Low
kr.252.30

Summary

Name Age Since Current Position

Lars Rasmussen

59 2016 Independent Chairman of the Board

Deborah Dunsire

57 2018 President, Chief Executive Officer, Interim Executive Vice President Research & Development

Lene Skole

60 2015 Deputy Chairman of the Board

Anders Goetzsche

51 2018 Chief Financial Officer, Executive Vice President

Peter Anastasiou

49 2017 Executive Vice President, North America

Lars Bang

56 2018 Executive Vice President, Product Development & Supply

Keld Flintholm Joergensen

2019 Executive Vice President, Chief Business Officer

Johan Luthman

2019 Executive Vice President, Head of Research & Development

Jacob Tolstrup

46 2017 Executive Vice President, Commercial Operations

Lars Holmqvist

59 2015 Director

Rikke Kruse Andreasen

48 2018 Director, Employee Representative

Henrik Sindal Jensen

49 2018 Director, Employee Representative

Ludovic Tranholm Otterbein

45 2018 Director, Employee Representative

Henrik Andersen

51 2018 Independent Director

Jeffrey Berkowitz

53 2018 Independent Director

Jeremy Levin

65 2017 Independent Director

Palle Holm Olesen

Vice President Investor Relations

Biographies

Name Description

Lars Rasmussen

Mr. Lars Soeren Rasmussen has served as Independent Chairman of the Board of Directors at H. Lundbeck A/S since March 31, 2016. Before that, he has been Independent Director of the Company since March 21, 2013. He is Member of the Company’s Audit Committee and Chairman of the Remuneration and Nomination Committee. He has management experience in global med-tech. He was responsible for various functions in the group, including global sales, innovation and production, both in Denmark and the United States. He is Member of the Board of Directors of William Demant Holding A/S and Chairman of Coloplast A/S.

Deborah Dunsire

Dr. Deborah L. Dunsire, M.D. has been appointed President and Chief Executive Officer of H. Lundbeck A/S, effective as of September 1, 2018 and she has been Interim Executive Vice President Research & Development since December 31, 2018. She brings more than 30 years of clinical, commercial, and international management experience from the biotech and pharmaceutical industry, primarily in the fields of oncology and CNS, thus bridging a breadth of scientific and business experience. Her professional and executive experience includes positions as President and CEO of XTuit Pharmaceuticals, Inc., FORUM Pharmaceuticals Inc. and Millennium Pharmaceuticals, Inc. She graduated from University of the Witwatersrand, South Africa in 1985 and is trained as a medical doctor.

Lene Skole

Ms. Lene Skole-Soerensen has been Deputy Chairman of the Board at H. Lundbeck A/S since March 25, 2015. She is CEO of Lundbeck Foundation and holds directorships in two subsidiaries. She is Member of the Remuneration and Nomination and Scientific Committees of the Company. She also serves as Deputy Chairman of the Boards of Oersted A/S, Falck A/S and ALK-Abello A/S and is Board Member of Tryg A/S and Tryg Forsikring A/S.

Anders Goetzsche

Mr. Anders Goetzsche has been Executive Vice President and Chief Financial Officer at H. Lundbeck A/S since September 1, 2018. He no longer serves as Interim Chief Executive Officer of the Company, effective as of August 31, 2018. He has held that position from November 1, 2017. He joined the Company in 2007. Prior to that, he was Chief Financial Officer for the Berlingske Officin, Director of Group Accounting and Reporting at Group 4 Falck and Sales Manager with the SAS Institute. He started his career in 1991 at PriceWaterhouseCoopers. Mr. Goetzsche is Member of the Board of Veloxis Pharmaceuticals A/Sand DFDS and Chairman of the Board of Rosborg Moebler A/S. He received a Master of Science degree in Accounting from Syddansk Universitet (University of Southern Denmark) in 1991, and became State Authorized Public Accountant in 1997.

Peter Anastasiou

Mr. Peter E. Anastasiou has been appointed Executive Vice President, North America at H. LUNDBECK A/S, effective as of November 1, 2017. Peter Anastasiou serves as President of Lundbeck North America, overseeing the operations of both the U.S. and Canadian businesses. Peter Anastasiou has been with Lundbeck since 2009 and has since early 2016 served as President of Lundbeck North America where he oversaw all aspects of the U.S. value chain, directing all Commercial, Drug Development and Corporate activities. Prior to that he served as U.S. Chief Commercial Officer, during which time he directed the Commercial operations of the company’s Psychiatry and Neurology franchises. Since mid-2016, Peter Anastasiou has had the responsibility for North America including Canada. Before joining Lundbeck, Peter Anastasiou held a series of leadership roles within neuroscience-focused pharmaceutical organizations. He served as Vice President of Marketing and Reimbursement at Neuronetics, Inc., and as Director of Abilify U.S. Marketing at Bristol-Meyers Squibb Company. He began his career at Eli Lilly and Company, where he held a variety of Marketing and Sales positions over the course of 11 years, including participation in the global launch of Cymbalta. He is Member of the Board of The Bear Necessities Pediatric Cancer Foundation and PhRMA (Pharmaceutical Research and Manufacturers of America).

Lars Bang

Mr. Lars Bang has served as Executive Vice President, Product Development & Supply at H. Lundbeck A/S since 2018. He has previously been Executive Vice President, Supply Operations & Engineering at the Company. He began his career at the Company in 1988 as Trainee in Research & Development (R&D). Over the years, he held such positions as Lunbeck's Divisional Director for Corporate Planning and Strategy; Group Senior Vice President Supply Operations and Engineering since 2003, and Senior Vice President, Sales & Marketing, among others. He joined the Executive Management in February 2016. Mr. Bang is Member of the Board of Directors of Fertin Pharma A/S, Claudio Bidco A/S, Claudio Hodco A/S and O.B. Holding Aps. He obtained a Master of Science degree in Engineering from Danmarks Tekniske Universitet in 1987 and a Bachelor of Commerce degree in Marketing from the Copenhagen Business School in 1989.

Keld Flintholm Joergensen

Mr. Keld Flintholm Joergensen has been appointed Executive Vice President, Chief Business Officer at H. LUNDBECK A/S effective as of April 4, 2019. He joins the Company from a position as Global Head of Strategic Partnering for Roche. Since 2011 Keld has worked in business development and partnering across multiple therapy areas, including CNS. During this period, he has been leading multiple global M&A projects, pharma and biotech partnering initiatives and strategic projects, building creative partnerships and deals to expand the Roche pipeline. Keld holds a BSc in Economics and Business Administration and a MSc in Business Economics and Auditing from Copenhagen Business School.

Johan Luthman

Dr. Johan Luthman has been appointed Executive Vice President, Head of Research & Development at H. LUNDBECK A/S effective as of March 1, 2019. He has approximately 28 years of experience in pharmaceutical R&D. Johan has been exposed to R&D management from companies such as Eisai, Merck & Co and AstraZeneca and has taken through development of small molecules and biopharmaceuticals (mAb and protein therapeutics) programs in neuroscience (neurology, psychiatry, pain and ophthalmology), metabolic diseases and immunology & inflammation areas. He graduated in Dental Sciences from Karolinska Institute in 1984. Johan also holds a PhD in Neurobiology and Histology.

Jacob Tolstrup

Mr. Jacob Tolstrup has been appointed Executive Vice President, Commercial Operations at H. Lundbeck A/S, effective as of November 1, 2017. He has previously been Executive Vice President, Corporate Functions at the Company since February 2016. Jacob Tolstrup began his career with Abbott Laboratories in 1997. In 1999, he joined Lundbeck and has since been working in a number of positions including Finance, Investor Relations and Communication and has worked in Lundbeck affiliates in the US for approximately four years. He was head of Corporate Functions which comprised Corporate Business Development, Corporate Human Resources, Investor Relations and Corporate Communication & Public Affairs. Jacob Tolstrup holds a Master of Science in Business Administration & Commercial Law from Aalborg University, Denmark and an MBA from European Business College, Munich, Germany.

Lars Holmqvist

Mr. Lars Erik Holmqvist has been Director of H. Lundbeck A/S since March 25, 2015. He is Member of the Audit Committee. He holds Master of Science in business administration. Lars Holmqvist is Senior Advisor within healthcare at Bain Capital. He previously served as Vice President responsible for sales and marketing at Pharmacia. In addition, he has held management positions in several pharma and med-tech companies including Boston Scientific Corporation, Medtronic, Applied Biosystems Group, DAKO and Agilent Technologies. Lars Holmqvist’s special qualifications for serving on Lundbeck’s Board of Directors include his international management experience, his expertise in finance and his sales and marketing experience from the global pharmaceutical, med-tech and life-science industry. Lars Holmqvist is Board Member at Lundbeck Foundation, ALK-Abello A/S, Tecan AG and Naka UK topco Ltd.

Rikke Kruse Andreasen

Ms. Rikke Kruse Andreasen has been Director, Employee Representative at H. LUNDBECK A/S since March 20, 2018. Rikke has been with Lundbeck since 1995 as a Senior Laboratory Technician. In 2012, she was elected as a Union Representative for the laboratory technicians and as a Work Council member. She is educated as a Laboratory Technician in 1991 at Laborantskolen Copenhagen, and in 2016 she completed a college education in Employment Law and Negotiation at Copenhagen Business School. Rikke Kruse Andreasen started working with Statens Serum Institut from 1991-1995 as Section Laboratory Technician. Since working with Lundbeck, she has been in three different departments as a Senior Laboratory Technician.

Henrik Sindal Jensen

Mr. Henrik Sindal Jensen has been Director, Employee Representative at H. Lundbeck A/S since December 2018. He previously was Director, Employee Representative from March 26, 2014 till March 20, 2018. Henrik has been employed with Lundbeck since 2004 and currently holds a position as Director in Corporate Business Development & Licensing. Before this, Henrik worked in research where he held a number of different positions including line and project management and most recently as Principal Scientist involved Lundbeck’s research projects. Henrik obtained his BSc and MSc degrees from the University of Aarhus and earned his industrial PhD degree in collaboration between the Graduate School of Neuroscience at the University of Copenhagen and NeuroSearch. Prior to joining Lundbeck, Henrik held positions as Assistant Professor at the Department of Medical Physiology, University of Copenhagen and as Research Assistant at the Department of Molecular and Structural Biology, University of Aarhus.

Ludovic Tranholm Otterbein

Mr. Ludovic Tranholm Otterbein has been Director, Employee Representative at H. LUNDBECK A/S since March 20, 2018. He is Member of the Board of Lundbeck Foundation. Ludovic has been with Lundbeck since 2011 and started as an external Lean Consultant. In his current role, Ludovic is the Director of Research Informatics and Compound management. Ludovic completed his MSc in France in 1998 at Polytech Marseille, before moving to the United States of America to complete his PhD in Biophysics working on muscular diseases. Before joining Lundbeck, Ludovic was a Senior Consultant at Valeocon Management Consulting where he helped clients within the pharmaceutical industry. Ludovic has also worked at AstraZeneca both in UK and Sweden from 2002-2010.

Henrik Andersen

Mr. Henrik M. Andersen has been Independent Director at H. LUNDBECK A/S since March 21, 2018. He is Chairman of the Audit Committee. He holds Master of Law and graduate diploma in Trade and Finance. Henrik Andersen is Group President and CEO of Hempel A/S. Prior to joining Hempel in 2016, Henrik Andersen was with ISS since 2000 where he held various positions. He was appointed to the Executive Board in ISS in 2011 first as CFO, later as Chief Operating Officer (COO) for EMEA and most recently Group COO. Henrik Andersen also spent seven years in the UK growing ISS UK as CEO. Before joining ISS, Henrik Andersen was in the financial industry for 10 years. Henrik Andersen's qualifications for serving on Lundbeck's Board of Directors include experience with accounting, finance, capital markets, international business and strategic management of international companies. Henrik Andersen is a member of the Board of Directors in Vestas A/S, member of the Board in Maj Invest Holding A/S (until April 2018) and member of The Investment Committee of Maj Invest Equity 4 K/S.

Jeffrey Berkowitz

Mr. Jeffrey (Jeff) Berkowitz, J.D. has been Independent Director of H. LUNDBECK A/S since March 20, 2018. He is Member of the Scientific Committee of the Company. He is Juris Doctor and BA in Political Science. Jeffrey Berkowitz has recently served as an Executive Vice President of UnitedHealth Group (UNH), and CEO of their Optum International subsidiary since 2016. He served as Executive Vice President and President of Pharma & Global Market Access at Walgreens Boots Alliance, Inc. from 2015 and served first as Senior Vice President of Pharmaceutical Development and Market Access of Walgreen Co then as President of Walgreens Boots Alliance Development in the period 2010 – 2015. From 1998 to 2009, he held a variety of positions with increasing responsibility in market access, sales and marketing with Schering-Plough prior to its acquisition by Merck in 2009. Prior to joining Schering-Plough, Jeffrey Berkowitz was a health care attorney for the international law firm Proskauer, LLP in New York and Washington, D.C. Jeffrey Berkowitz's special qualifications for serving on Lundbeck's Board of Directors include global experience with payers, pharmaceutical companies, specialty and retail pharmacies and wholesalers with responsibility for generic and branded procurement and inventory management, as well as pricing, reimbursement, specialty pharmacy and health care strategies. He and his team led the joint venture between Walgreens and Alliance Boots based in Bern, Switzerland and were key drivers of the merger surpassing aggressive synergy targets. Jeffrey Berkowitz has also been recognized in PharmaVoice magazine as one of the 100 Most Inspiring Leaders in the Life Sciences in 2009, 2010 and 2012 and serves on the Editorial Boards of Life Science Leader and Pharmaceutical Commerce magazines. Jeffrey Berkowitz is independent director of Infinity Pharmaceuticals, Inc. and Esperion Therapeutics, Inc.

Jeremy Levin

Dr. Jeremy Max Levin has served as Independent Member of the Board of H. Lundbeck A/S since March 30, 2017. He is Chairman of the Company’s Scientific Committee. He holds MA and DPhil in Molecular Biology and MB BChir Medicine and Surgery. Jeremy M. Levin has more than 25 years of experience in the global pharmaceuticals industry, leading companies and people to develop and commercialize medicines that address compelling medical needs worldwide. Since 2014, he has been CEO and chairman of Ovid Therapeutics, a New York-based neurology company focused on rare and orphan diseases of the brain. Previously, Jeremy M. Levin served as President & CEO of Teva Pharmaceuticals and before becoming CEO of Teva, he was a member of the Executive Committee of Bristol-Myers Squibb where he was globally responsible for overall strategy, alliances and business development. Prior to that, he was Global Head of Strategic Alliances at Novartis, where he established and managed strategic collaborations with multiple companies and research institutions around the world. Jeremy M. Levin’s special qualifications for serving on Lundbeck’s Board of Directors include a robust blend of clinical insight and experience, business development skills, corporate strategy and financial savvy. In addition he has substantial board experience. Jeremy M. Levin is member of the Board of Directors of BioCon in India, ZappRx and on the Board and Executive Committee of BIO, the Biotechnology Innovation Organization in the USA.

Palle Holm Olesen